Top Message
Creating synergies together as One PHC,
striving to become a leader in the future of healthcare
Kyoko DeguchiPresident, Representative Director and CEO
PHC Holdings Corporation
We would like to express our sincere gratitude to our shareholders for their continued support.
In modern society, particularly in Japan, the rapid progression of aging is leading to an increase in various chronic diseases such as diabetes, cardiovascular conditions, and dementia. Under these circumstances, there is a growing demand for more advanced and personalized treatments. At the same time, the widening regional disparities in access to medical care and healthcare infrastructure have become pressing challenges.
PHC Group is working hard toward the realization of a society where high-quality healthcare is accessible to more people at a more affordable cost. We are committed to improving healthcare quality and accessibility while enhancing cost-effectiveness through three focus areas: Monitoring (Prevention, Prognosis, & Management), Examination/Diagnosis/Treatment, and Research & Development. We contribute to these areas by “enabling appropriate condition management and early detection of disease,” “delivering accurate and rapid testing and measurement,” and “driving efficiencies in research practice and drug discovery.”
PHC Group is working toward achieving its “Value Creation Plan 2027” under the vision, “Be a leader in precision technology that powers the future of healthcare,” established in autumn 2024. PHC Group is comprised of multiple business entities with different histories and cultures. It is vital that we maximize synergies across business operations while leveraging each of their unique strengths. The key to enhancing group-wide competitiveness and recognition while respecting this diversity is the spirit of “co-creation,” encapsulated in our slogan “One PHC.” We are also advancing a shift within our operational and technical functions, from remaining focused within their own domains to collaborating actively with other areas of the business. I am personally passionate about building an organization where every employee takes ownership of our business priorities and proactively contributes to value creation.
Building on our foundation of precision technology, we will co-create the future of healthcare with medical professionals and researchers and pave the way for improving lives and the health of society. As a global company originating from Japan, we invite you to join us in looking forward to the PHC Group's contributions to creating a prosperous society.
About PHC Group
Brand, Products and Services
PHC Group offers a wide range of products and services from research to diagnosis, treatment, and prevention of disease, with a global presence in three domains: Diabetes Management, Healthcare Solutions, and Diagnostics & Life Sciences.
Wemex Corporation, in the Healthcare Solutions domain, absorbed its subsidiary, Wemex Healthcare Systems Corporation, in October 2025. Through this integration, we will combine
the strengths of both companies and further accelerate the roll-out of cloud-based solutions tailored to the government-led digital transformation in healthcare.
Additionally, in September 2025, regarding the sales business of the Continuous Glucose Monitoring (CGM) system, Eversense® in the Diabetes Management Domain, PHC Holdings Corporation and its subsidiary, Ascensia Diabetes Care, signed a memorandum of understanding regarding the business transfer with Senseonics Holdings, Inc., the manufacturer of the product. The decision was made to establish an integrated framework at Senseonics for the development, manufacturing, and sales of Eversense®, creating the optimal environment to accelerate its growth. This decision is based on the PHC Group’s strategy outlined in its "Value Creation Plan 2027," which emphasizes investment efficiency and strengthening portfolio management. We will continue to build an optimal organizational structure aligned with our growth strategy.
Details of the PHC Group's main products and services are available in the virtual showroom on our website. We invite you to take a look.
Sustainability
PHC Group aims to achieve sustainable growth and enhance long-term corporate value through a unified approach to integrating management strategy, Human Capital strategy, and ESG strategy. Based on our materiality topics, we have established KPIs and targets for fiscal 2030 and are steadily advancing our initiatives.
Participation in Initiatives and Rating
PHC Group obtained "Near-Term SBT" certification from the Science Based Targets initiative (SBTi), an international initiative, for its greenhouse gas (GHG) emissions reduction targets toward fiscal year 2030. We will continue to advance specific initiatives addressing climate change and contribute to realizing a sustainable society.
PHC Group was named to Group 1, the highest-scoring group for the “Morningstar Japan ex-REIT Gender Diversity Tilt Index,” developed by Morningstar Inc., a leading investment research provider. This recognition reflects our achievements in key areas, including the proportion of female managers, childcare support programs, career development, and recruitment strategies. We will continue to incorporate diverse perspectives and strive to enhance corporate value.
PHC Group has earned a Bronze Medal in the sustainability assessment conducted by EcoVadis, ranking among the top 35% of companies evaluated worldwide. Our Value Creation Plan 2027, announced in November 2024 originally set to achieve the Bronze Medal by the end of fiscal year 2027 as a target. However, by achieving the success of our initiatives, we have been able to achieve this goal in the first fiscal year.
PHC Group is committed to collaborating with all stakeholders to continue our sustainability initiatives and contribute to the health of society.
- * Morningstar, Inc., and/or one of its affiliated companies (individually and collectively, “Morningstar”) has authorized PHC Holdings Corporation to use of the Morningstar® Japan ex-REIT Gender Diversity Tilt Logo (“Logo”) to reflect the fact that, for the designated ranking year, PHC Holdings Corporation ranks within the top group of companies comprising the Morningstar® Japan ex-REIT Gender Diversity Tilt Index℠ (“Index”) on the issue of gender diversity in the workplace. Morningstar is making the Logo available for use by PHC Holdings Corporation solely for informational purposes. Use of the Logo should not be construed as an endorsement by Morningstar of PHC Holdings Corporation or as a recommendation, offer or solicitation to purchase, sell or underwrite any security associated with. The Index is designed to reflect gender diversity in the workplace in Japan, but Morningstar does not guarantee the accuracy, completeness or timeliness of the Index or any data included in it. Morningstar makes no express or implied warranties regarding the Index or the Logo, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the Index, any data included in it or the Logo. Without limiting any of the foregoing, in no event shall Morningstar or any of its third-party content providers have any liability for any damages (whether direct or indirect), arising from any party’s use or reliance on the Index or the Logo, even if Morningstar is notified of the possibility of such damages. The Morningstar name, Index name and the Logo are the trademarks or services marks of Morningstar, Inc. Past performance is no guarantee of future results.
Release of the “Integrated Report 2025”
In October 2025, we published the “Integrated Report 2025.” The report features our Group’s growth strategy and value creation process for innovating the future of healthcare, as well as interviews with our management team and employees. We encourage you to take a look.
Topics
LiCellMo™ Wins “2025 R&D 100 Award”
The Biomedical Division of PHC Corporation was honored with a “2025 R&D 100 Award” from R&D World, a science and technology publication in the United States, for its Live Cell Metabolic Analyzer, LiCellMo™. The "R&D 100 Awards" is an international science and technology award established in 1963 that annually recognizes the 100 most innovative technologies developed over the past year. This is the only science and technology award that recognizes newly commercialized products, technologies and materials for their technological significance.
LiCellMo™ provides continuous real time data on key cellular metabolic pathways*, offering researchers unprecedented visibility into dynamic changes in cell states.
Together with the Cell Expansion System "LiCellGrow™," which is scheduled for future launch, we aim to contribute to the acquisition of new insights in research and the advancement of treatment methods.
- * A series of biochemical reactions within cultured cells that produce the energy required for cellular functions and survival.
Renewal of Compact Immunoassay Analyzer “PATHFAST®”
In Vitro Diagnostics Division of PHC Corporation has started selling the newly improved Immunoanalyzer “PATHFAST®.” This product is a compact, tabletop immune chemiluminescence analyzer that is easy to relocate and is utilized in a wide range of medical settings, from large hospitals to clinics.
In the latest renewal, the device has been updated with a larger, more intuitive operation screen design and a wide-opening door that allows for smooth handling of reagents. Additionally, it features a built-in barcode reader and a status indicator lamp that visualizes the device's condition, further enhancing usability. Having marked its 20th anniversary since its launch, "PATHFAST®" has contributed to rapid testing in medical settings across approximately 50 countries, including Japan and the United States, in Europe, Asia, the Middle East, and Latin America.
Launch of the “Medicom Cloud-Based EMR System,” Integrated with Medical-Receipt Function for Clinics
Wemex Corporation officially launched the “Medicom cloud-based EMR system" integrated with a medical-receipt computer for clinics in April 2025. This product is the first fully cloud-based electronic medical record system offered by the company, which has led the electronic medical record market for over 25 years since 1999. With features such as an intuitive user interface, document creation support, and AI-powered automatic calculation functions, "Medicom cloud-based EMR system” is designed to be user-friendly for physicians and staff, enabling improved operational efficiency. Additionally, over 150 support centers across Japan assist with system implementation and operation. In October 2025, we released a functional update to the system, adding the following features: Input for outsourced test requests and test result confirmation, Data migration from third-party systems, Expanded device integration, and Improved user interface design. Since its launch, the system has received positive feedback from customers for its high usability, prevention of calculation omissions, and efficiency in document creation.
In the spring of 2026, we plan to introduce specialized input and billing support for electronic medical record information-sharing services. Moving forward, we remain committed to continuously enhancing the customer experience.
LSI Medience Corporation Reacquires ISO 15189 Accreditation for Central Laboratory
LSI Medience Corporation reacquired ISO 15189 accreditation dated November 28, 2025. The Central Laboratory of LSI Medience Corporation had its ISO 15189 accreditation cancelled by the ISO Accreditation Organization on July 26, 2024 due to inappropriate quality management. However, after undergoing an audit in October 2025, it has now successfully reacquired the ISO 15189 accreditation.
Please note that no report of harm to patients’ health caused by the inappropriate quality management has been identified up to this point in time. We sincerely apologize again to our customers and stakeholders including shareholders and investors for any concern and inconvenience that this has caused.
PHC Holdings Corporation and LSI Medience have been making every effort to reinstate and recover trust by thoroughly implementing corrective actions and recurrence prevention measures based on the suggestions of the final report of the external investigation committee. We will continue our improvement activities and strive to further restore trust.
Financial Highlights
Financial Highlights (1H)
Revenue decreased due to negative FX impact. Operating profit increased, mainly due to BGM revenue and the effects of profitability improvement efforts.
Basic information (As of September 30, 2025)
- Total number of authorized shares
- 460,000,000
- Total number of issued shares
- 126,721,820
- Number of shareholders
- 25,945
Status of major shareholders
| Shareholder name | Shareholding rate(%) |
|---|---|
| KKR PHC Investment L.P. | 37.9 |
| Mitsui & Co.,Ltd. | 17.3 |
| Mitsubishi Chemical Corporation | 9.7 |
| Panasonic Holdings Corporation | 7.7 |
| LCA 3 Moonshot LP | 4.5 |
| The Master Trust Bank of Japan, Ltd. (Investment account) | 3.4 |
| Hidetomo Oka | 0.9 |
| PHC Holdings Employee Stock Ownership Plan | 0.7 |
| Custody Bank of Japan, Ltd. (Investment account) | 0.5 |
| INTERACTIVE BROKERS LLC | 0.4 |
- Shareholding rate is calculated upon deducting the treasury shares (211,941 shares).
- Rounded to the nearest tenth
Holder distribution data
- Individual and others13.0％
- Financial institution4.0％
- Other domestic corporations35.4％
- Foreign corporations, etc.46.8％
- Securities company0.7％
- Treasury stock0.2％
- Rounded to the nearest tenth